The United States Food and Drug Administration has chosen Dr Vinay Prasad to lead its Center for Biologics Evaluation and Research.

CBER’s new chief has argued for more stringent measures of assessing drugs for cancer and rare diseases, suggesting he might ...

In his new role with the FDA, Dr. Vinay Prasad will oversee the regulation of costly drugs, including vaccines, gene ...

Vinay Prasad oversees vaccines, gene therapies and the blood supply. His views raise alarms for pharmaceutical companies and ...

has chosen Dr Vinay Prasad, a professor at the University of California-San Francisco, to lead its Center for Biologics Evaluation and Research. The division oversees vaccines and biologic ...

We want you to take advantage of everything Cancer Therapy Advisor has to offer. To view unlimited content, log in or register for free.

From claiming COVID vaccines were perfect and would end the pandemic to treating rare, temporary vaccine side-effects, even ...

President Donald Trump unwrapped a massive drug pricing policy as CMS prepares for the next round of Medicare drug price negotiations; Vinay Prasad to take the helm at the FDA’s Center for Biologics ...

The question on many minds among FDA rank-and-file in attendance was: Which Prasad would show up? The 2010s Prasad -- a ...

While Prasad’s views may not align with many of the FDA’s traditional policies, they do fit into a broader MAHA agenda of ...

Vinay Prasad has worked as a professor of medicine, haematologist/oncologist, and health policy researcher. Controversial doctor Vinay Prasad, a public health ...

To hear Vinay ... Prasad’s views on medicine will be of considerable importance moving forward, after the physician and academic was named the next head of the FDA’s Center for Biologics ...